Journal: Bioscience Reports

Article Title: Applying vibration in early postmenopausal osteoporosis promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells and suppresses postmenopausal osteoporosis progression

doi: 10.1042/bsr20191011

Figure Lengend Snippet: Figure 7. Effect of LMV or E2 on ERα, Wnt3a, and β-catenin expression in rBMSCs (A) The changes of mRNA expression in rBMSCs were detected by qRT-PCR, including ERα, Wnt3a, and β-catenin. (B) The changes of protein expression in rBMSCs were detected by Western blotting, including ERα, Wnt3a, and β-catenin. *P<0.05, **P<0.01 vs.

Article Snippet: Primary antibodies used in the present study included those against β-actin, ERα, Wnt3a, and β-catenin (Proteintech, U.S.A.).

Techniques: Expressing, Quantitative RT-PCR, Western Blot

Journal: bioRxiv

Article Title: Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor

doi: 10.1101/2024.03.29.587397

Figure Lengend Snippet: (A) Schematic of the ERα antibody-based NIR fluorescent nanosensor detection concept. (B) NIR fluorescent spectra of the construct nanosensor in PBS. Success of the antibody conjugation to base construct was assessed by (C) comparison of decay in correlation coefficient as a function of time for SWCNT-(TAT) 6 -NH 2 and ERα antibody (Ab) conjugated to SWCNT- (TAT) 6 , (D) Change in zeta potential for ssDNA-SWCNT compared to the ERα nanosensor. Difference in means = 9.1 mV, p = 0.006.

Article Snippet: To initially evaluate the response of the ERα nanosensor complex in buffer, we first measured the fluorescence response of 0.5 mg/L nanosensor to 250 nM human ERα (Catalog number NBP2-34478PEP, Novus Biologicals; Colorado, USA) in 1x PBS using a near-infrared (NIR) fluorescent cuvette-based spectrometer (NS MiniTracer; Applied NanoFluorescence, Texas, USA).

Techniques: Construct, Conjugation Assay, Comparison, Zeta Potential Analyzer

Journal: bioRxiv

Article Title: Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor

doi: 10.1101/2024.03.29.587397

Figure Lengend Snippet: (A) Response of the nanosensor (7,6) chirality to 250 nM recombinant ERα in PBS. Difference in means = 3.5 nm, p = 0.004. (B) Response of the nanosensor (7,6) chirality to 250 nM recombinant ERα in 10% FBS. Difference in means = 1 nm, p = 0.002. (C) Change in center wavelength of the (7,5) chirality for the nanosensor incubated with ER- or ER+ cells. Difference in means = 5.5 nm, p = 0.04).

Article Snippet: To initially evaluate the response of the ERα nanosensor complex in buffer, we first measured the fluorescence response of 0.5 mg/L nanosensor to 250 nM human ERα (Catalog number NBP2-34478PEP, Novus Biologicals; Colorado, USA) in 1x PBS using a near-infrared (NIR) fluorescent cuvette-based spectrometer (NS MiniTracer; Applied NanoFluorescence, Texas, USA).

Techniques: Recombinant, Incubation

Journal: bioRxiv

Article Title: Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor

doi: 10.1101/2024.03.29.587397

Figure Lengend Snippet: (A) Schematic of direct nanosensor response measurement to ER+ breast cancer patient cells. (B) Change in center wavelength of the nanosensor (7,5) chirality after incubation with ER- or ER+ breast cancer biopsy aspirates. Difference in means = 2.3 nm, p = 0.0011. (C) Change in center wavelength of the nanosensor (7,6) chirality after incubation with ER- or ER+ breast cancer biopsy aspirates. Difference in means = 1.6 nm, p = 0.0002. (D) Change in center wavelength of the nanosensor (9,4) chirality after incubation with ER- or ER+ breast cancer biopsy aspirates. Difference in means = 1.2 nm, p = 0.0001. (E) Receiver operating characteristic evaluation of the ability of each chirality to differentiate ER-from ER+ biopsy samples. AUC is area under the curve. p(7,5) = 0.0020, (7,6) = 0.017, (9,4) = 0.0029.

Article Snippet: To initially evaluate the response of the ERα nanosensor complex in buffer, we first measured the fluorescence response of 0.5 mg/L nanosensor to 250 nM human ERα (Catalog number NBP2-34478PEP, Novus Biologicals; Colorado, USA) in 1x PBS using a near-infrared (NIR) fluorescent cuvette-based spectrometer (NS MiniTracer; Applied NanoFluorescence, Texas, USA).

Techniques: Incubation

Journal: bioRxiv

Article Title: Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor

doi: 10.1101/2024.03.29.587397

Figure Lengend Snippet: (A) Schematic representing the fractionation method to measure the change in center wavelength for bound vs. unbound nanosensor. (B) Change in center wavelength of the nanosensor each chirality of the “Washed Bound” fraction. Only the (7,6) chirality (center) exhibited a significant change. Difference in the means for this sample = 3.1 nm, p = 0.025. (C) Change in center wavelength of the nanosensor each chirality of the “Washed Unbound” fraction. No differences were statistically significant. (D) ROC comparison of the three measurements (from & ) and the ability of each chirality to differentiate ER-from ER+ cells. Only the Unwashed method was statistically significant (please refer to for AUC and p values for each).

Article Snippet: To initially evaluate the response of the ERα nanosensor complex in buffer, we first measured the fluorescence response of 0.5 mg/L nanosensor to 250 nM human ERα (Catalog number NBP2-34478PEP, Novus Biologicals; Colorado, USA) in 1x PBS using a near-infrared (NIR) fluorescent cuvette-based spectrometer (NS MiniTracer; Applied NanoFluorescence, Texas, USA).

Techniques: Fractionation, Comparison

Journal: Cellular & Molecular Biology Letters

Article Title: E0703 targets ERβ to facilitate the upregulation of GLI3, thereby alleviating irradiation-induced DNA damage on lymphocytes

doi: 10.1186/s11658-025-00821-8

Figure Lengend Snippet: ERβ serves as a direct target of E0703 to transactivate the gene expression of GLI3 . CETSA ( A ), DARTS ( B ), and molecular docking ( C and D ) assays were adopted to analyze the binding of E0703 to ERβ and ERα. SPR analysis of the binding affinity of E0703 to the ERβ protein, with the apparent equilibrium dissociation constant (Kd) calculated ( E ). Protein expression of ERβ was detected by cell immunofluorescence ( F ) and western blot ( G ). Using selective antagonists of ERβ (PHTPP) and ERα (AZD9496), cell viability ( H ) and DNA damage ( I ) improved by E0703 were demonstrated to be mediated by ERβ. ERβ enrichment on the promoter region of GI3 could be triggered by E0703 ( J ), which significantly promoted the protein expression of GLI3 and triggered ATM-CHK2 signaling ( K ). Stimulation of ATM-CHK2 signaling triggered by E0703 was also mediated by ERβ ( L ). Cells in three independent plates were subjected to Calcein AM/PI double staining assay; fluorescence intensities of three independent cells were obtained in γH2AX staining assay; and gray values for three independent bands were obtained in western blot. Representative images are shown. * P < 0.05, ** P < 0.01, *** P < 0.001, or **** P < 0.0001 indicated significant differences. ns, no significance

Article Snippet: KU-55933 (ATM antagonist), BML-277 (CHK2 antagonist), AZD9496 (ERα antagonist), PHTPP (ERβ antagonist), and SBI0640756 (eIF4G1 antagonist) were all purchased from MedChemExpress to inhibit the corresponding signaling pathways.

Techniques: Gene Expression, Binding Assay, Expressing, Immunofluorescence, Western Blot, Double Staining, Fluorescence, Staining